Actinium Pharmaceuticals Class Action Lawsuit Filed

Rosen Law Firm has filed a class action lawsuit against Actinium Pharmaceuticals, alleging that the company made false and misleading statements to investors between October 31, 2022, and August 2, 2024. The lawsuit claims that Actinium Pharmaceuticals' data from its Sierra Trial was unlikely to satisfy the United States — Food and Drug Administration's guidelines for the approval of its Iomab-B Biologics License Application. Furthermore, additional analyses provided by Actinium Pharmaceuticals to the United States — Food and Drug Administration to mitigate poor Overall Survival data were also deemed unlikely to satisfy the agency's guidelines. As a result, the United States — Food and Drug Administration was expected to refuse to review or approve the Iomab-B BLA in its current form, leading to investor damages. Philip Kim and Lawrence Rosen of Rosen Law Firm are encouraging affected investors to join the class action, with a lead plaintiff deadline of May 26, 2025.